B-cell lymphoma in retrieved femoral heads: a long term follow up.
BACKGROUND
A relatively high incidence of pathological conditions in retrieved femoral heads, including a group of patients having low grade B-cell lymphoma, has been described before. At short term follow up none of these patients with low-grade B-cell lymphoma showed evidence of systemic disease. However, the long term follow up of these patients is not known.


METHODS
From November 1994 up to and including December 2005 we screened all femoral heads removed at the time of primary total hip replacement histopathologically and included them in the bone banking protocol according to the guidelines of the American Associations of Tissue Banks (AATB) and the European Association of Musculo-Skeletal Transplantation (EAMST). We determined the percentage of B-cell lymphoma in all femoral heads and in the group that fulfilled all criteria of the bone banking protocol and report on the long-term follow-up.


RESULTS
Of 852 femoral heads fourteen (1.6%) were highly suspicious for low-grade B-cell lymphoma. Of these 852 femoral heads, 504 were eligible for bone transplantation according to the guidelines of the AATB and the EAMST. Six femoral heads of this group of 504 were highly suspicious for low-grade B-cell lymphoma (1.2%). At long term follow up two (0.2%) of all patients developed systemic malignant disease and one of them needed medical treatment for her condition.


CONCLUSIONS
In routine histopathological screening we found variable numbers of low-grade B-cell lymphoma throughout the years, even in a group of femoral heads that were eligible for bone transplantation. Allogenic transmission of malignancy has not yet been reported on, but surviving viruses are proven to be transmissible. Therefore, we recommend the routine histopathological evaluation of all femoral heads removed at primary total hip arthroplasty as a tool for quality control, whether the femoral head is used for bone banking or not.
Zwitser
Eline W
EW
Department of Orthopaedic Surgery, VU University Medical Center, Amsterdam, The Netherlands. ewzwitser@hotmail.com
de Gast
Arthur
A
Basie
Mirjam J A
MJ
van Kemenade
Folkert J
FJ
van Royen
Barend J
BJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019644:Arthroplasty, Replacement, Hip / Q000592:standards; D018586:Bone Banks / Q000592:standards*; D016025:Bone Transplantation / Q000009:adverse effects*; D018450:Disease Progression; D018562:Disease Transmission, Infectious / Q000517:prevention & control; D005260:Female; D005270:Femur Head / Q000473:pathology / Q000637:transplantation*; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D016393:Lymphoma, B-Cell / Q000453:epidemiology* / Q000473:pathology; D008297:Male; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D013997:Time Factors; D020858:Tissue and Organ Harvesting / Q000592:standards; D014184:Transplantation, Homologous / Q000009:adverse effects*; D055815:Young Adult